Rigel Pharmaceuticals (RIGL) Receivables (2013 - 2026)

Rigel Pharmaceuticals' Receivables history runs 13 years deep, the most recent figure standing at $50.9 million for Q1 2026.

• In Q1 2026, Receivables rose 1566.5% year-over-year to $50.9 million; the TTM figure through Mar 2026 stood at $50.9 million (up 1566.5% YoY), while the FY2025 annual figure was $52.7 million, up 26.55% from the prior year.
• Receivables for Q1 2026 stood at $50.9 million, down from $52.7 million in the prior quarter.
• The five-year high for Receivables was $52.7 million in Q4 2025, with the low at $3.1 million in Q1 2025.
• The 5-year median for Receivables is $28.9 million (2024), against an average of $29.0 million.
• The sharpest annual moves came in 2022 and 2026: Receivables sank 89.28% in 2022, then soared 1566.5% in 2026.
• Rigel Pharmaceuticals' Receivables stood at $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024, then advanced by 26.55% to $52.7 million in 2025, then declined by 3.26% to $50.9 million in 2026.
• Business Quant data shows RIGL's Receivables at $50.9 million in Q1 2026, $52.7 million in Q4 2025, and $46.0 million in Q3 2025.